Williams, Ingram, Mitchell to join President's Cancer Panel

What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.”

On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.

November 08, 2024

By Paul Goldberg

At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS

As the Trump administration stands poised to redraft the nation’s public health priorities, the American Cancer Society, one of the most prominent advocates for cancer patients, finds itself in an interregnum, following an abrupt departure of its Chief Executive Officer Karen E. Knudsen.

November 08, 2024

By Paul Goldberg

Clinical Trials & Tribulations

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more

November 08, 2024

By Otis W. Brawley

Conversation with The Cancer Letter

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant. This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I...

November 08, 2024

By Jacquelyn Cobb

Conversation with The Cancer Letter

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S.

A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA’s cancer czar Richard Pazdur had a “silver anniversary” at the agency recently. So, he invited some guests—the commissioners he had reported to under the Democratic and Republican administrations.

November 01, 2024

Vol.50 No.41

By Claire Marie Porter

Williams, Ingram, Mitchell to join President’s Cancer Panel

YOU MAY BE INTERESTED IN

What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.”

At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S.

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

Renew today!

Subscriber content

Login

Williams, Ingram, Mitchell to join President’s Cancer Panel

YOU MAY BE INTERESTED IN

What will Trump’s return to the White House mean for oncology?“Our work just got a lot more difficult.”

At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS

A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinicsThe state has the second highest (and rising) cancer rates in the U.S.

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

Login

What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.”

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S.